Skip to main content
Erschienen in: International Urology and Nephrology 1/2013

01.02.2013 | Urology - Original Paper

Preoperative prognostic factors after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma

verfasst von: Shuichi Morizane, Hideto Iwamoto, Toshihiko Masago, Akihisa Yao, Tadahiro Isoyama, Takehiro Sejima, Atsushi Takenaka

Erschienen in: International Urology and Nephrology | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the clinical significance of preoperative biomarkers such as laboratory data, Eastern Cooperative Oncology Group Performance Status (ECOG PS) and clinicopathological factors in patients undergoing radical nephroureterectomy for upper urinary tract urothelial carcinoma.

Methods

Between 1995 and 2011, a total of 99 patients treated at our institution for upper urinary tract urothelial carcinoma were enrolled in this study. The prognostic significance of various preoperative data and clinicopathological factors were analyzed. Univariate and multivariate analyses were performed using the Kaplan–Meier method with the log-rank test and a Cox proportional hazards regression model.

Results

Median patient age was 73 years (range 44–86 years), and the median follow-up period after radical nephroureterectomy was 37.9 months (range 6.6–171.4 months). The 5-year intravesical recurrence-free survival and cancer-specific survival estimates were 47.1 and 70.0 %, respectively. On multivariate analysis, concomitant bladder carcinoma was an independent predictor of intravesical recurrence (hazard ratio 3.689; P = 0.002), and infiltration (hazard ratio 14.842; P = 0.002), preoperative serum creatinine level (hazard ratio 9.992; P = 0.005), preoperative serum hemoglobin level (hazard ratio 6.370; P = 0.018) and ECOG PS (hazard ratio 4.326; P = 0.037) were associated with worse cancer-specific survival. This study is limited by biases associated with its retrospective design.

Conclusions

This study indicates that not only clinicopathological factors, but also preoperative biomarkers, such as serum creatinine and hemoglobin levels and ECOG PS, predict a poor survival in patients with upper urinary tract urothelial carcinoma.
Literatur
1.
Zurück zum Zitat David KA, Mallin K, Milowsky MI, Ritchey J, Carroll PR, Nanus DM (2009) Surveillance of urothelial carcinoma: stage and grade migration, 1993–2005 and survival trends, 1993–2000. Cancer 115(7):1435–1447PubMedCrossRef David KA, Mallin K, Milowsky MI, Ritchey J, Carroll PR, Nanus DM (2009) Surveillance of urothelial carcinoma: stage and grade migration, 1993–2005 and survival trends, 1993–2000. Cancer 115(7):1435–1447PubMedCrossRef
2.
Zurück zum Zitat Pieras E, Frontera G, Ruiz X, Vicens A, Ozonas M, Piza P (2010) Concomitant carcinoma in situ and tumour size are prognostic factors for bladder recurrence after nephroureterectomy for upper tract transitional cell carcinoma. BJU Int 106(9):1319–1323PubMedCrossRef Pieras E, Frontera G, Ruiz X, Vicens A, Ozonas M, Piza P (2010) Concomitant carcinoma in situ and tumour size are prognostic factors for bladder recurrence after nephroureterectomy for upper tract transitional cell carcinoma. BJU Int 106(9):1319–1323PubMedCrossRef
3.
Zurück zum Zitat Matsui Y, Utsunomiya N, Ichioka K, Ueda N, Yoshimura K, Terai A, Arai Y (2005) Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology 65(2):279–283PubMedCrossRef Matsui Y, Utsunomiya N, Ichioka K, Ueda N, Yoshimura K, Terai A, Arai Y (2005) Risk factors for subsequent development of bladder cancer after primary transitional cell carcinoma of the upper urinary tract. Urology 65(2):279–283PubMedCrossRef
4.
Zurück zum Zitat Raman JD, Ng CK, Boorjian SA, Vaughan ED Jr, Sosa RE, Scherr DS (2005) Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology. BJU Int 96(7):1031–1035PubMedCrossRef Raman JD, Ng CK, Boorjian SA, Vaughan ED Jr, Sosa RE, Scherr DS (2005) Bladder cancer after managing upper urinary tract transitional cell carcinoma: predictive factors and pathology. BJU Int 96(7):1031–1035PubMedCrossRef
5.
Zurück zum Zitat Ku JH, Choi WS, Kwak C, Kim HH (2011) Bladder cancer after nephroureterectomy in patients with urothelial carcinoma of the upper urinary tract. Urol Oncol 29(4):383–387PubMedCrossRef Ku JH, Choi WS, Kwak C, Kim HH (2011) Bladder cancer after nephroureterectomy in patients with urothelial carcinoma of the upper urinary tract. Urol Oncol 29(4):383–387PubMedCrossRef
6.
Zurück zum Zitat Azemar MD, Comperat E, Richard F, Cussenot O, Roupret M (2011) Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. Urol Oncol 29(2):130–136PubMedCrossRef Azemar MD, Comperat E, Richard F, Cussenot O, Roupret M (2011) Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. Urol Oncol 29(2):130–136PubMedCrossRef
7.
Zurück zum Zitat Soga N, Arima K, Sugimura Y (2008) Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Int J Urol 15(9):800–803PubMedCrossRef Soga N, Arima K, Sugimura Y (2008) Adjuvant methotrexate, vinblastine, adriamycin, and cisplatin chemotherapy has potential to prevent recurrence of bladder tumors after surgical removal of upper urinary tract transitional cell carcinoma. Int J Urol 15(9):800–803PubMedCrossRef
8.
Zurück zum Zitat Chung SD, Huang KH, Lai MK, Huang CY, Chen CH, Pu YS, Yu HJ, Chueh SC (2007) CKD as a risk factor for bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. Am J Kidney Dis 50(5):743–753PubMedCrossRef Chung SD, Huang KH, Lai MK, Huang CY, Chen CH, Pu YS, Yu HJ, Chueh SC (2007) CKD as a risk factor for bladder recurrence after nephroureterectomy for upper urinary tract urothelial carcinoma. Am J Kidney Dis 50(5):743–753PubMedCrossRef
9.
10.
Zurück zum Zitat Zigeuner R, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Weizer A, Kikuchi E, Remzi M, Raman JD, Bolenz C, Bensalah K, Capitanio U, Koppie TM, Kassouf W, Sircar K, Patard JJ, Fernandez MI, Wood CG, Montorsi F, Strobel P, Wheat JC, Haitel A, Oya M, Guo CC, Ng C, Chade DC, Sagalowsky A, Langner C (2010) Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol 57(4):575–581PubMedCrossRef Zigeuner R, Shariat SF, Margulis V, Karakiewicz PI, Roscigno M, Weizer A, Kikuchi E, Remzi M, Raman JD, Bolenz C, Bensalah K, Capitanio U, Koppie TM, Kassouf W, Sircar K, Patard JJ, Fernandez MI, Wood CG, Montorsi F, Strobel P, Wheat JC, Haitel A, Oya M, Guo CC, Ng C, Chade DC, Sagalowsky A, Langner C (2010) Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol 57(4):575–581PubMedCrossRef
11.
Zurück zum Zitat Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG (1998) Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 52(4):594–601PubMedCrossRef Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG (1998) Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 52(4):594–601PubMedCrossRef
12.
Zurück zum Zitat Favaretto RL, Shariat SF, Chade DC, Godoy G, Adamy A, Kaag M, Bochner BH, Coleman J, Dalbagni G (2010) The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol 58(4):574–580PubMedCrossRef Favaretto RL, Shariat SF, Chade DC, Godoy G, Adamy A, Kaag M, Bochner BH, Coleman J, Dalbagni G (2010) The effect of tumor location on prognosis in patients treated with radical nephroureterectomy at Memorial Sloan-Kettering Cancer Center. Eur Urol 58(4):574–580PubMedCrossRef
13.
Zurück zum Zitat Cho KS, Hong SJ, Cho NH, Choi YD (2007) Grade of hydronephrosis and tumor diameter as preoperative prognostic factors in ureteral transitional cell carcinoma. Urology 70(4):662–666PubMedCrossRef Cho KS, Hong SJ, Cho NH, Choi YD (2007) Grade of hydronephrosis and tumor diameter as preoperative prognostic factors in ureteral transitional cell carcinoma. Urology 70(4):662–666PubMedCrossRef
14.
Zurück zum Zitat Rink M, Robinson BD, Green DA, Cha EK, Hansen J, Comploj E, Margulis V, Raman JD, Ng CK, Remzi M, Bensalah K, Kabbani W, Haitel A, Rioux-Leclercq N, Guo CC, Chun FK, Kikuchi E, Kassouf W, Sircar K, Sun M, Sonpavde G, Lotan Y, Pycha A, Karakiewicz PI, Scherr DS, Shariat SF (2012) Impact of Histological Variants on Clinical Outcomes of Patients with Upper Urinary Tract Urothelial Carcinoma. J Urol 189:398–404CrossRef Rink M, Robinson BD, Green DA, Cha EK, Hansen J, Comploj E, Margulis V, Raman JD, Ng CK, Remzi M, Bensalah K, Kabbani W, Haitel A, Rioux-Leclercq N, Guo CC, Chun FK, Kikuchi E, Kassouf W, Sircar K, Sun M, Sonpavde G, Lotan Y, Pycha A, Karakiewicz PI, Scherr DS, Shariat SF (2012) Impact of Histological Variants on Clinical Outcomes of Patients with Upper Urinary Tract Urothelial Carcinoma. J Urol 189:398–404CrossRef
15.
Zurück zum Zitat Novara G, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Bastian PJ, Martinez-Salamanca JI, Seitz C, Lemberger RJ, Burger M, El-Hakim A, Baba S, Martignoni G, Gupta A, Karakiewicz PI, Ficarra V, Shariat SF (2010) Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol 57(6):1064–1071PubMedCrossRef Novara G, Matsumoto K, Kassouf W, Walton TJ, Fritsche HM, Bastian PJ, Martinez-Salamanca JI, Seitz C, Lemberger RJ, Burger M, El-Hakim A, Baba S, Martignoni G, Gupta A, Karakiewicz PI, Ficarra V, Shariat SF (2010) Prognostic role of lymphovascular invasion in patients with urothelial carcinoma of the upper urinary tract: an international validation study. Eur Urol 57(6):1064–1071PubMedCrossRef
16.
Zurück zum Zitat Li WM, Li CC, Ke HL, Wu WJ, Huang CN, Huang CH (2009) The prognostic predictors of primary ureteral transitional cell carcinoma after radical nephroureterectomy. J Urol 182(2):451–458PubMedCrossRef Li WM, Li CC, Ke HL, Wu WJ, Huang CN, Huang CH (2009) The prognostic predictors of primary ureteral transitional cell carcinoma after radical nephroureterectomy. J Urol 182(2):451–458PubMedCrossRef
17.
Zurück zum Zitat Saito K, Kawakami S, Ohtsuka Y, Fujii Y, Masuda H, Kumagai J, Kobayashi T, Kageyama Y, Kihara K (2007) The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int 100(2):269–273PubMedCrossRef Saito K, Kawakami S, Ohtsuka Y, Fujii Y, Masuda H, Kumagai J, Kobayashi T, Kageyama Y, Kihara K (2007) The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int 100(2):269–273PubMedCrossRef
18.
Zurück zum Zitat Sengelov L, Kamby C, Schou G, von der Maase H (1994) Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract. Cancer 74(1):123–133PubMedCrossRef Sengelov L, Kamby C, Schou G, von der Maase H (1994) Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract. Cancer 74(1):123–133PubMedCrossRef
19.
Zurück zum Zitat Kuroda M, Kotake T, Akaza H, Hinotsu S, Kakizoe T (1998) Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Jpn J Clin Oncol 28(8):497–501PubMedCrossRef Kuroda M, Kotake T, Akaza H, Hinotsu S, Kakizoe T (1998) Efficacy of dose-intensified MEC (methotrexate, epirubicin and cisplatin) chemotherapy for advanced urothelial carcinoma: a prospective randomized trial comparing MEC and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin). Jpn J Clin Oncol 28(8):497–501PubMedCrossRef
20.
Zurück zum Zitat Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466–475PubMedCrossRef Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K (2006) Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49(3):466–475PubMedCrossRef
21.
Zurück zum Zitat Duggan BJ, Gray SB, McKnight JJ, Watson CJ, Johnston SR, Williamson KE (2004) Oligoclonality in bladder cancer: the implication for molecular therapies. J Urol 171(1):419–425PubMedCrossRef Duggan BJ, Gray SB, McKnight JJ, Watson CJ, Johnston SR, Williamson KE (2004) Oligoclonality in bladder cancer: the implication for molecular therapies. J Urol 171(1):419–425PubMedCrossRef
22.
Zurück zum Zitat Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG, Upper Tract Urothelial Carcinoma CollaborationThe Upper Tract Urothelial Carcinoma C (2009) Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 115(6):1224–1233PubMedCrossRef Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG, Upper Tract Urothelial Carcinoma CollaborationThe Upper Tract Urothelial Carcinoma C (2009) Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 115(6):1224–1233PubMedCrossRef
23.
Zurück zum Zitat Bircan S, Candir O, Kapucuoglu N (2005) The effect of tumor invasion patterns on pathologic stage of bladder urothelial carcinomas. Pathol Oncol Res 11(2):87–91PubMedCrossRef Bircan S, Candir O, Kapucuoglu N (2005) The effect of tumor invasion patterns on pathologic stage of bladder urothelial carcinomas. Pathol Oncol Res 11(2):87–91PubMedCrossRef
24.
Zurück zum Zitat Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, Culine S, von der Maase H, Vaughn DJ, Rosenberg JE (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28(11):1850–1855PubMedCrossRef Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, Winquist E, Culine S, von der Maase H, Vaughn DJ, Rosenberg JE (2010) Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 28(11):1850–1855PubMedCrossRef
25.
Zurück zum Zitat Martinez-Salamanca JI, Shariat SF, Rodriguez JC, Chromecki TF, Ficarra V, Fritsche HM, Kassouf W, Matsumoto K, Cabello LO, Seitz C, Tritschler S, Walton TJ, Zattoni F, Novara G (2012) Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: an international study. BJU Int 109(8):1155–1161PubMedCrossRef Martinez-Salamanca JI, Shariat SF, Rodriguez JC, Chromecki TF, Ficarra V, Fritsche HM, Kassouf W, Matsumoto K, Cabello LO, Seitz C, Tritschler S, Walton TJ, Zattoni F, Novara G (2012) Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: an international study. BJU Int 109(8):1155–1161PubMedCrossRef
26.
Zurück zum Zitat Trivanovic D, Petkovic M, Stimac D (2009) New prognostic index to predict survival in patients with cancer of unknown primary site with unfavourable prognosis. Clin Oncol 21(1):43–48CrossRef Trivanovic D, Petkovic M, Stimac D (2009) New prognostic index to predict survival in patients with cancer of unknown primary site with unfavourable prognosis. Clin Oncol 21(1):43–48CrossRef
27.
Zurück zum Zitat Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91(12):2214–2221PubMedCrossRef Caro JJ, Salas M, Ward A, Goss G (2001) Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 91(12):2214–2221PubMedCrossRef
28.
Zurück zum Zitat Yurut-Caloglu V, Caloglu M, Kaplan M, Inci O (2009) Pre-treatment hemoglobin levels are important for bladder carcinoma patients with extravesical extension undergoing definitive radiotherapy. Asian Pac J Cancer Prev 10(6):1151–1157PubMed Yurut-Caloglu V, Caloglu M, Kaplan M, Inci O (2009) Pre-treatment hemoglobin levels are important for bladder carcinoma patients with extravesical extension undergoing definitive radiotherapy. Asian Pac J Cancer Prev 10(6):1151–1157PubMed
Metadaten
Titel
Preoperative prognostic factors after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma
verfasst von
Shuichi Morizane
Hideto Iwamoto
Toshihiko Masago
Akihisa Yao
Tadahiro Isoyama
Takehiro Sejima
Atsushi Takenaka
Publikationsdatum
01.02.2013
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 1/2013
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-012-0347-1

Weitere Artikel der Ausgabe 1/2013

International Urology and Nephrology 1/2013 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.